ALK and non-small cell lung carcinoma: Therefore, we carried out this large, single‐center, real‐world study to investigate the specific clinicopathological characteristics of ALK‐positive advanced NSCLC compared with ALK‐negative ones, and to give more clinical evidence of the treatment of crizotinib in ALK‐positive patients in the real world.